The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

epinephrine and glucagon rapidly increase the amount of active phosphorylase in pre-incubated liver slices 1,2. In order to study the nature of the change in the phosphorylase molecule ...

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia single ascending dose (SAD) study of the oral ...

Catalent’s acquisition by Novo Holdings, to help Novo Nordisk meet manufacturing demand for glucagon-like peptide (GLP)-1 obesity medicines, has taken sterile fill-finish capacity out of the market, ...

The start-up expects to advance its lead asset—a once-weekly oral glucagon-like peptide 1 (GLP-1) receptor agonist—into Phase 2 trials for weight loss and the treatment of obesity later this year.

This includes a Phase II-ready oral glucagon-like peptide-1 receptor agonist (GLP-1RA) ecnoglutide, a potential first-in-class oral amylin agonist, and a long-acting subcutaneous amylin agonist. These ...

Within the past several years, multiple drugs that take aim at the glucagon-like peptide-1 receptor ... caused the cells to burn extra ATP—a molecule used for energy—without transporting ...

Attempts to design small molecule therapies directed to this cytokine have not led to approved products yet. Here we report the discovery and development of a potent small molecule inhibitor of TNF ...